In our previous study, decreased S-specific Ab levels were observed only in patients with IBD treated with anti-TNF, whereas S-specific Ab responses of patients with rheumatic disease were not affected, potentially due to the lower doses of anti-TNF agents used (8). Here, TNF is linked to inflammatory bowel disease.